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Abstract
Hemodialysis aims at removing uremic toxins thus decreasing their concentrations. The present study investigated whether
Kt/Vurea, used as marker of dialysis adequacy, is correlated with these concentrations. Predialysis blood samples were taken
before a midweek session in 71 chronic HD patients. Samples were analyzed by colorimetry, HPLC, or ELISA for a broad
range of uremic solutes. Solute concentrations were divided into four groups according to quartiles of Kt/Vurea, and also of
different other parameters with potential impact, such as age, body weight (BW), Protein equivalent of Nitrogen
Appearance (PNA), Residual Renal Function (RRF), and dialysis vintage. Dichotomic concentration comparisons were
performed for gender and Diabetes Mellitus (DM). Analysis of Variance in quartiles of Kt/Vurea did not show significant
differences for any of the solute concentrations. For PNA, however, concentrations showed significant differences for urea
(P,0.001), uric acid (UA), p-cresylsulfate (PCS), and free PCS (all P,0.01), and for creatinine (Crea) and hippuric acid (HA)
(both P,0.05). For RRF, concentrations varied for b2-microglobulin (P,0.001), HA, free HA, free indoxyl sulfate, and free
indole acetic acid (all P,0.01), and for p-cresylglucuronide (PCG), 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid
(CMPF), free PCS, and free PCG (all P,0.05). Gender and body weight only showed differences for Crea and UA, while age,
vintage, and diabetes mellitus only showed differences for one solute concentration (UA, UA, and free PCS, respectively).
Multifactor analyses indicated a predominant association of concentration with protein intake and residual renal function. In
conclusion, predialysis concentrations of uremic toxins seem to be dependent on protein equivalent of nitrogen
appearance and residual renal function, and not on dialysis adequacy as assessed by Kt/Vurea. Efforts to control intestinal
load of uremic toxin precursors by dietary or other interventions, and preserving RRF seem important approaches to
decrease uremic solute concentration and by extension their toxicity.
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Introduction
Failure of the kidneys is associated with the gradual retention of
a myriad of solutes [1], causing an endogenous intoxication and
failure of almost all organ systems [2,3]. Dialysis aims at removing
those solutes, resulting in a decrease of their concentration and
hence also their biological toxicity.
Quantification of the removal of these toxins may offer a useful
tool to evaluate the adequacy of a given approach, but might also
lead to misconceptions, e.g. by abandoning attempts to further
improve a removal strategy once a set target is reached.
Traditionally, Kt/Vurea is the marker of dialysis adequacy that is
most widely used on a regular basis. In some countries, reaching a
threshold Kt/Vurea is even a prerequisite for reimbursement of
dialysis [4].
When considering observational data, one cannot deny that the
introduction of Kt/Vurea in 1985 helped to gradually improve
survival of the dialysis population [5–8]. The parameter was
however developed in an era when dialysis was almost exclusively
performed over relatively short sessions with small pore dialyzers
[9]. Many strategic modifications have meanwhile been intro-
duced, such as large pore membranes, convection, frequent
dialysis and extended dialysis. All these alternative strategies
enhance solute removal [10–16] and have been associated with
improved outcome [15,17–23], but do not necessarily increase
Kt/Vurea [10,11,22,23]. Also the number of known uremic toxins
has extended [24,25], mostly with compounds that are difficult to
remove by standard dialysis.
In two recent studies, we demonstrated in CKD patients not yet
on dialysis that estimated GFR (eGFR), as the main currently used
marker of renal function, was barely and inconsistently associated
with concentrations of uremic toxins, although the latter are
associated with organ dysfunction [26,27]. This divergence was
attributed to a greater impact on uremic solute concentration by
factors other than GFR, such as diet, intestinal generation,
metabolism and tubular secretion [28].
Thus, the question could be raised in how far this would be true
as well for the main marker of dialysis adequacy Kt/Vurea.
Although Kt/Vurea is mathematically related to the concentration
change during dialysis, one could assume that keeping this
parameter at a higher threshold would result in a decrease of
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uremic solute concentration as a consequence of more efficient
removal, also before dialysis.
An additional asset of performing this type of study in
hemodialysis, is that in this setting, it is quite easy to assess
objectively dietary protein intake, one of the potentially impacting
factors [29]. Remarkably enough, this question has to the best of
our knowledge never been studied, although a recent review
pointed to the theoretical possibility that Kt/Vurea would not be an
accurate marker for uremic solute removal and retention [21].
Therefore, in this study we want to clarify: 1/whether Kt/Vurea
is representative for the concentration of a broad array of uremic
toxins in patients on hemodialysis; 2/whether there is a difference
in uremic toxin concentrations depending on other patient
characteristics such as age, body weight, protein equivalent of
nitrogen appearance, residual renal function, dialysis vintage,
gender, and diabetes mellitus.
Patients and Methods
Ethics Statement
The study was approved by the local Ethics Committee (Ethical
Committee, Ghent University Hospital, Ghent, Belgium) and
performed in accordance to the Declaration of Helsinki. Written
informed consent was obtained from all participants.
Patients
All chronic hemodialysis patients, older than 18 years, with a
residual renal function lower than 10 mL/min, and dialyzed in
our centre during the day, were considered for inclusion. Patients
were on maintenance hemodialysis for at least three months
during which the same hemodialyzer, dialysis duration, blood and
dialysate flows, convective strategy, and vascular access had been
applied. Dialysis dose, expressed as Kt/Vurea is calculated monthly
according to the single-pool Daugirdas formula [30] to check
accordance to the EBPG [31], and is only adapted if the value goes
below threshold. The general exclusion criteria were active
infection, pregnancy, unstable condition, and vascular access
problems.
Sampling and data collection
Predialysis blood samples were taken during a midweek session,
immediately centrifuged (3000 rpm corresponding to 1250 g),
aliquoted, and stored at 280uC until analysis. Postdialysis blood
samples, as needed for the calculation of Kt/Vurea and PNA, were
taken immediately after discontinuation of the dialysis session after
slowing the blood pump to 100 mL/min during 15 s.
Urea [molecular weight MW: 60D] and creatinine (Crea) [MW:
113D] were measured by standard laboratory methods.
Different solutes, most of them protein bound, were determined
by high performance liquid chromatography (HPLC): uric acid
(UA) [168D], hippuric acid (HA) [179D, protein binding
(PB),50%], 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid
(CMPF) [240D - PB,100%], indoxyl sulfate (IS) [213D -
PB,90%], indole acetic acid (IAA) [175D - PB,65%], p-
cresylsulfate (PCS) [187D - PB,95%], and p-cresylglucuronide
(PCG) [284D - PB,10%]. To determine the total fraction, serum
samples were first deproteinized by heat denaturation [32] and
analyses were performed by reverse-phase HPLC. IS and IAA
(excitation lex:280 nm; emission lem:340 nm) and PCS and PCG
(lex:265 nm; lem:290 nm) were determined by fluorescence
analysis, and HA and CMPF were analyzed by UV detection at
254 nm [14]. Free fractions were determined according to Fagugli
et al [14].
ELISA kits manufactured by DLD Diagnostika GmbH
(Hamburg, Germany) were used for measuring asymmetric
dimethylarginine (ADMA) [202D], symmetric dimethylarginine
(SDMA) [202D] after acylation. For beta-2-microglobulin (b2M)
[11.8 kD], ELISA kits of Orgentec Diagnostika GmbH (Mainz,
Germany) were used.
For each patient, the following additional parameters were
registered: age, gender, body weight (BW), presence of diabetes
mellitus (DM), dialysis vintage, and medication, while Kt/Vurea,
residual renal function (RRF), and protein equivalent of nitrogen
appearance (PNA) were calculated as explained below.
Calculations
Since the single treatment dose as measured during a
midweek dialysis session does not reflect the average clearance
both by exogenous hemodialysis and endogenous residual renal
clearance, we calculated weekly Kt/Vurea accounting for
ultrafiltration and residual renal function according to Daugir-
das et al [33]:
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with F the number of dialysis sessions per week, Kru the residual
renal urea clearance (mL/min), UFw the weekly fluid removal
(L), V the urea distribution volume (L) as calculated according
to Daugirdas and Smye [34], and S the standard Kt/V
according to Leypoldt:
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with t the treatment time (min), and eKt/V calculated according
to [35]:
eKt=V~spKt=V:
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And spKt/V calculated according to Daugirdas et al [30]:
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with BUNpre and BUNpost the pre and post dialysis Blood Urea
Nitrogen concentration, UF the ultrafiltration volume, and BW
the post dialysis body weight.
Residual Renal Function (RRF) was calculated as the arithmetic
mean of the creatinine and urea clearance (ClCrea and Clurea,
respectively):
RRF~average ClCrea,Clureað Þ ð5Þ
with:
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with Curine and Vurine (mL) the concentration and volume of the
urine as collected during the interdialytic period Dtinter (h), and
Cstart and Cend the blood concentrations at the start and end of the
interdialytic period. Herewith, Cstart was corrected for the post-
dialysis rebound as [36]:
Cstart~Cpre:
Cpost
Cpre
  t
tzR ð7Þ
With Cpre and Cpost the pre and immediate post-dialysis
concentrations, and R the rebound time, i.e. 35 min for urea
and 70 min for Crea.
Finally, the Protein equivalent of Nitrogen Appearance (PNA) at
midweek was calculated according to the K/DOQI and EBPG
[37,38]:
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Statistical analyses
For the patient characteristics age, BW, Kt/Vurea, PNA, and
dialysis vintage, the median and 25th and 75th percentile were
calculated and, per characteristic, patients were divided into
four groups according to quartiles. Since the median of RRF
was zero, the four groups for this parameter were not defined by
quartiles but consisted of one group to which all anuric patients
were selected (n = 40), whereas the remaining non-anuric
patients were distributed in tertiles (n = 10–11 each). For gender
and DM, patients were divided in two groups according to
male/female and DM/non DM. With these data, non-
parametric analysis of variance (Kruskal-Wallis) tests were
performed to check potential differences in uremic toxin
concentrations among the groups.
Furthermore, correlations (Spearman) were evaluated between
uremic toxin concentrations and the different studied character-
istics; finally, multifactor analyses per solute were performed.
The data of patients taking allopurinol were excluded from the
analysis considering uric acid.
Data are expressed as mean 6 standard deviation for normal
distributions, or as medians with the 25th and 75th percentiles for
non normal distributions.
P,0.05 was considered to be statistically significant. All
statistical analyses were performed using SPSS Statistics 19 (SPSS
Inc, Chicago, IL) for Windows (Microsoft Corp, Redmond, WA).
Results
Seventy-four chronic hemodialysis patients fulfilled the
inclusion criteria. Two of them declined written consent, and
1 patient had an interdialytic interval of 2.5 days at midweek
instead of 1.5 days. The 71 chronic hemodialysis patients
included were on thrice weekly hemodialysis for 38.0 (19.5–
61.5) months: 26/45 females/males, 28 diabetes mellitus, 31
with RRF, age 72 (63.0–80.0) years, body weight 69.0 (61.3–
78.8) kg, weekly Kt/Vurea 2.43 (2.28–2.63), and PNA 0.83
(0.74–1.01) g/kg/day (Table 1).
Our patients were routinely dialyzed for 245618 min, with a
blood flow of 321637 mL/min (QB range 220–350 mL/min) and
QD=500 mL/min in hemodialysis mode with either an FX8
(Fresenius Medical Care, Germany) (n = 5), or Evodial (Gambro,
Sweden) (n = 1) dialyzer, or in postdilution hemodiafiltration mode
with either an FX800 (Fresenius Medical Care, Germany) (n = 41),
Phylter 17SD (Bellco, Italy) (n = 7), Xenium 210 (Baxter, USA)
(n = 6), PHF (Bellco, Italy) (n = 4), Polyflux 170H (Gambro,
Sweden) (n = 4), or Surflux 170UH (Nipro, Japan) (n = 3) dialyzer.
All patients had a permanent vascular access: i.e. 42 fistulas and 29
tunneled central venous catheters.
An overview of the measured predialysis concentrations of
uremic solutes is given in Table 2. The percentage differences
between minimum and maximum concentrations among the
patients ranged from 72.0 (UA) to 99.5% (total and free PCG)
(Table 2); normalizing concentrations to Kt/Vurea resulted in the
same percentage differences between the minimum and maximum
values (data not shown).
Table 3 shows the P-values of the Kruskal-Wallis tests for the
concentrations under study if patient characteristics were separat-
ed in quartiles or dichotomically. The main characteristics
associated with a significant difference of solute concentrations
were PNA and RRF (Table 3 and Figure 1). For Kt/Vurea no
single significant difference was found.
Table 4 shows the R and P-values of the Spearman
correlations between solute concentrations and patient charac-
teristics. Kt/Vurea showed a correlation only with the concen-
tration of Crea. PNA, on the contrary, showed significant
correlations for the majority of solutes with R= 0.894 for urea,
and a value in the range 0.4–0.6 for UA, PCS, and free PCS,
and 0.2–0.4 for Crea, HA, IS, PCG, free HA, and free PCG.
RRF showed inversed correlations with an R-value in the range
20.4 to 20.6 for b2M, HA, free HA, and free IAA, and with R
between 20.2 and 20.4 for IS, PCG, free IS, free PCS, and free
PCG.
Also in multifactor analysis, PNA and RRF were the main
factors associated with uremic solute concentration, except for
Crea, and this occurred mainly independently (Table 5).
Table 1. Patient characteristics and Kt/V values.
Median (25th–75th percentile)*
Gender (female/male) 26/45
DM (yes/no) 28/43
RRF (yes/no) 31/40
Allopurinol (yes/no) 7/64
Age (years) 72.0 (63.0–80.0)
BW (kg) 69.0 (61.3–78.8)
spKt/V 1.62 (1.45–1.89)
eKt/V 1.43 (1.28–1.66)
weekly Kt/V 2.43 (2.28–2.63)
PNA (g/kg/day) 0.83 (0.74–1.01)
Dialysis vintage (months) 38.0 (19.5–61.5)
*if applicable.
DM: diabetes mellitus, BW: body weight, RRF: residual renal function, PNA:
protein equivalent of nitrogen appearance.
doi:10.1371/journal.pone.0076838.t001
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Table 2. Uremic toxin concentrations.
median (25th–75thp) [(75th-25th)/75th]?100 min - max [(max-min)/max]?100
urea 0.90 (0.71–1.06) 33.5 0.18–1.88 90.4
Crea 7.19 (5.77–9.01) 36.0 3.35–14.9 80.4
ADMA 1.00 (0.84–1.18) 28.2 0.51–1.93 73.6
SDMA 2.08 (1.73–2.48) 30.3 0.77–3.79 79.7
UA 6.53 (5.62–7.06) 20.3 2.55–9.11 72.0
b2M 39.4 (28.5–48.1) 40.8 13.9–96.3 89.6
HA 2.94 (1.47–5.64) 74.0 0.24–14.21 98.3
IS 1.80 (1.27–2.77) 54.4 0.29–5.75 97.7
IAA 0.18 (0.13–0.23) 42.7 0.07–0.73 90.9
PCS 2.94 (1.73–4.36) 60.2 0.06–7.53 99.2
PCG 0.49 (0.18–0.89) 79.8 0.02–3.94 99.5
CMPF 0.38 (0.20–0.61) 68.0 0.06–1.37 95.8
Free HA 1.65 (0.70–3.32) 79.0 0.13–9.09 98.6
Free IS 0.11 (0.06–0.23) 72.4 0.02–0.72 97.8
Free IAA 0.06 (0.04–0.07) 48.1 0.02–0.22 91.2
Free PCS 0.18 (0.11–0.33) 66.4 0.04–0.66 94.7
Free PCG 0.48 (0.17–0.86) 80.1 0.02–3.59 99.5
mg/dL, except urea in g/L, b2M in mg/mL, and ADMA and SDMA in mmol/L.
Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric dimethylarginine, UA: uric acid, b2M: beta-2-microglobulin, HA: hippuric acid, IS: indoxyl sulfate,
IAA: indole acetic acid, PCS: p-cresylsulfate, PCG: p-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.
doi:10.1371/journal.pone.0076838.t002
Table 3. P-values of comparison between concentrations for characteristics as divided in quartiles or dichotomically.
Age BW Kt/V PNA RRF vintage gender DM
urea 0.097 0.116 0.478 ,0.001 0.265 0.219 0.310 0.728
Crea 0.129 0.015 0.339 0.027 0.345 0.441 0.004 0.842
ADMA 0.616 0.458 0.396 0.848 0.337 0.683 0.492 0.814
SDMA 0.408 0.891 0.297 0.548 0.196 0.794 0.797 0.668
UA 0.002 0.026 0.097 0.004 0.240 0.026 0.025 0.171
b2M 0.898 0.666 0.585 0.607 ,0.001 0.644 0.346 0.916
HA 0.539 0.577 0.602 0.036 0.004 0.268 0.247 0.378
IS 0.850 0.462 0.340 0.261 0.159 0.664 0.839 0.259
IAA 0.678 0.251 0.583 0.203 0.089 0.959 0.437 0.402
PCS 0.283 0.698 0.809 0.001 0.815 0.739 0.452 0.312
PCG 0.230 0.786 0.391 0.067 0.041 0.766 0.273 0.291
CMPF 0.065 0.537 0.316 0.464 0.073 0.984 0.865 0.106
Free HA 0.491 0.580 0.629 0.092 0.002 0.181 0.277 0.384
Free IS 0.505 0.605 0.620 0.266 0.006 0.772 0.976 0.110
Free IAA 0.633 0.219 0.480 0.660 0.002 0.978 0.440 0.107
Free PCS 0.263 0.604 0.858 0.007 0.050 0.601 0.445 0.036
Free PCG 0.205 0.763 0.409 0.070 0.038 0.777 0.300 0.317
Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric dimethylarginine, UA: uric acid, b2M: beta-2-microglobulin, HA: hippuric acid, IS: indoxyl sulfate,
IAA: indole acetic acid, PCS: p-cresylsulfate, PCG: p-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.
BW: body weight, PNA: protein equivalent of nitrogen appearance, RRF: residual renal function, DM: diabetes mellitus.
P,0.05 is indicated in bold.
doi:10.1371/journal.pone.0076838.t003
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Discussion
In a group of 71 hemodialysis patients, variances were studied
for a broad range of predialysis uremic toxin concentrations as
functions of different patients characteristics and Kt/Vurea. The
most important findings are that different quartiles of Kt/Vurea did
not show any variations in serum concentration of the studied
solutes, whereas quartiles of PNA and RRF showed significant
variations of serum levels for 6 and 8 solutes under study,
respectively. For correlation analysis, only one association was
found for Kt/Vurea, whereas there were 10 associations for PNA
and 9 for RRF, pointing into the same direction as the analysis per
quartiles.
UA, ADMA, PCS, IS, and b2M have repeatedly been
associated with vascular damage and mortality in renal and
general populations [39–49]. In our study, quartiles of weekly Kt/
Vurea did not show any significant variance in serum concentration
of these solutes as was also found for spKt/V and eKt/V (data not
shown). The weekly Kt/Vurea, per definition accounting for RRF,
was correlated to only one investigated solute concentration, while
no correlations were found when considering spKt/V or eKt/V
(data not shown). On the other hand, subdivision for quartiles of
PNA showed differences in the serum concentration of UA, PCS,
urea, Crea, HA, and free PCS, and showed, additionally,
correlations with the concentrations of IS, PCG, free HA, and
free PCG. Furthermore, quartiles of RRF showed differences for
b2M, HA, PCG, and free concentrations of HA, IS, IAA, PCS,
and PCG, and showed, additionally, correlations with the IS
concentrations. Hence, from the present study, Kt/Vurea does not
seem to be a very good predictor of uremic solute concentrations,
not even in the subpopulation of patients without any residual
renal function (data not shown).
During the last decade, it became clear that dialysis dose, as
measured by the removal of a low-molecular weight solute such as
urea as is the case with Kt/Vurea, may not entirely be a parameter
of dialysis adequacy. Kinetics of urea differ from that of other
uremic solutes, even when these are small and water soluble like
urea is [50,51]. Furthermore, increasing dialysis time from 4 up to
8 hours, without changing the quantity of processed blood and
dialysate, did not impact Kt/Vurea, whereas, b2M, a middle
molecule and phoshate, a small but difficult to remove solute,
showed an increase by 81 and 49% respectively [11]. The present
study here adds that not only solute removal but also predialysis
solute concentration is not reflected in Kt/Vurea. At first sight, this
could be an evident conclusion, since Kt/Vurea is mathematically
related to the change in urea concentration during dialysis rather
than to the absolute concentration. However, the ultimate goal of
hemodialysis is to decrease absolute toxic solute concentrations,
and with it, the biological activity of uremic toxins. Hence, keeping
the adequacy parameter Kt/Vurea above the prescribed threshold
should result in decreased concentrations.
Fairly similar deceiving results, pleading against a unique
universal marker of uremic solute removal, were obtained in two
recent studies evaluating the associations of uremic retention solute
concentrations with estimated Glomerular Filtration Rates (eGFR)
in patients of Chronic Kidney Disease (CKD) stage 2 to 5, not on
dialysis [26,27]. These data strongly suggest that other factors than
GFR are more powerful determinants of serum solute concentra-
tion [26]. These include renal tubular secretion (IS, HA) [52],
metabolic factors (ADMA) [53], intestinal secretion, absorption
Figure 1. Box plots of quartiles and correlations of different solute concentrations versus Kt/V, PNA, and RRF: urea in g/L (panels A,
B, and C), b2M in mg/mL (panels D, E, and F), HA in mg/dL (panels G, H, and I), and free PCS in mg/dL (panels J, K, and L). b2M: beta-2-
microglobulin, HA: hippuric acid, PCS: p-cresylsulfate, PNA: protein equivalent of nitrogen appearance, RRF: residual renal function.
doi:10.1371/journal.pone.0076838.g001
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and generation (UA) [54], (indoles, phenols) [29,55,56], (IS)
[57,58].[26,59,60]. Impressive differences in serum concentration
of different solutes, either adjusted or not for Kt/Vurea, were found
in our present study (ranging from 72 to close to 100%),
confirming previous data in another hemodialyzed population
(concentration differences ranging from 66 to 100%) [26], so that
the same interfering factors may also play an as important role in
dialysis patients as in non-dialyzed CKD patients.
We found that residual renal function (RRF) distinguishes well
among solute concentrations. This confirms previous findings that
RRF has a higher impact on patient outcome than a high
delivered Kt/Vurea [61], and that RRF is better associated with
optimal nutritional status than dialysis adequacy [62]. In addition,
even limited increments of RRF are substantially more important
than dialyzer clearance as a determinant of b2M concentrations in
patients on high flux hemodialysis [63] and even hemodiafiltra-
tion, in spite of enhanced b2M clearance with this strategy due to
convection [64,65]. Also for the protein bound compounds, RRF
has a major contribution to total solute removal of patients on
dialysis [66,67].
The contribution of RRF to the differences between patients in
the serum concentration of b2M is in correspondence with the
inverse associations between RRF and another middle molecule,
Fibroblast Growth Factor-23 (FGF23) as previously found in a
prospective observational cohort study in peritoneal and hemodi-
alysis patients [68].
Our findings for RRF as predictor for most uremic solute
concentrations in the dialysis population do not fully match our
previous findings for eGFR as predictor for solute concentrations
in CKD 2–5 patients not on dialysis [69–72]. This might be due to
a difference in calculation of the renal function: i.e. while RRF in
this study is assessed directly using concentrations of Crea and
urea in blood and urine, in our previous studies eGFR was
estimated only using blood concentrations of Crea and/or CystC
[69–72]. In addition, GFR in the present dialysis population is
much lower than in the earlier CKD stages, whereas dialysis is an
additional confounder affecting concentration. Thus conditions in
between studies were entirely different.
Our data with regards to residual renal function point into the
same direction as those recently reported by Marquez et al [69–
72], also showing inverse correlations between protein bound
solute concentrations and residual renal function, even if they did
not take into account a measure of protein intake such as PNA.
Regarding PNA, significant correlations were found with
predialysis urea concentrations, as could be expected from the
PNA formula (equation 8). However, PNA is also well related to
Table 4. P and R-values for Spearman correlations between
the solute concentrations and the different patient
characteristics.
Age BW Kt/V PNA RRF vintage
urea P 0.007 0.511 0.230 ,0.001 0.561 0.210
R 20.320 0.894
Crea P 0.009 0.009 0.048 0.004 0.207 0.332
R 20.311 0.312 20.237 0.336
ADMA P 0.657 0.880 0.118 0.577 0.608 0.950
SDMA P 0.552 0.962 0.160 0.211 0.427 0.470
UA P ,0.001 0.041 0.058 0.001 0.243 0.007
R 20.446 0.256 0.373 20.336
b2M P 0.913 0.837 0.742 0.506 ,0.001 0.305
R 20.415
HA P 0.962 0.490 0.668 0.005 ,0.001 0.232
R 0.330 20.431
IS P 0.967 0.196 0.801 0.046 0.022 0.282
R 0.237 20.272
IAA P 0.658 0.602 0.140 0.801 0.101 0.782
PCS P 0.456 0.941 0.712 ,0.001 0.829 0.809
R 0.529
PCG P 0.825 0.734 0.651 0.003 0.004 0.540
R 0.349 20.335
CMPF P 0.003 0.154 0.576 0.562 0.080 0.559
R 0.346
Free HA P 0.840 0.398 0.824 0.024 ,0.001 0.229
R 0.267 20.453
Free IS P 0.953 0.361 0.870 0.131 0.001 0.668
R 20.380
Free IAA P 0.964 0.451 0.084 0.525 ,0.001 0.653
R 20.410
Free PCS P 0.959 0.612 0.664 ,0.001 0.028 0.238
R 0.445 20.261
Free PCG P 0.792 0.746 0.639 0.003 0.004 0.536
R 0.346 20.337
Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric
dimethylarginine, UA: uric acid, b2M: beta-2-microglobulin, HA: hippuric acid, IS:
indoxyl sulfate, IAA: indole acetic acid, PCS: p-cresylsulfate, PCG:
p-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.
BW: body weight, PNA: protein equivalent of nitrogen appearance, RRF: residual
renal function.
P,0.05 is indicated in bold. R values only shown in case of significant P.
doi:10.1371/journal.pone.0076838.t004
Table 5. Multifactor analysis: covariates with cumulative R-
value.
Solute Covariates/R-value of full model
Urea PNA/0.894
Crea PNA/0.336 Kt/V/0.624
ADMA
SDMA
UA PNA/0.373
b2M RRF/20.415
HA RRF/20.431
IS RRF/20.272
IAA
PCS PNA/0.529
PCG PNA/0.349 RRF/0.441
CMPF age/0.346
Free HA RRF/20.453
Free IS RRF/20.380
Free IAA RRF/20.410
Free PCS PNA/0.445
Free PCG PNA/0.346 RRF/0.438
Empty cells indicate that the correlation analysis did not include other elements
that contributed significantly.
doi:10.1371/journal.pone.0076838.t005
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substantial differences in serum concentrations of many other
solutes under study. These data are consistent with growing
evidence that food protein intake and its intestinal processing, to a
large extent regulated by the gut microbiota, plays an important
role in uremic toxin generation, especially in relation with protein
bound molecules derived from amino acid metabolites such as
indole or p-cresol [29,73,74]. Of note, whereas quartiles of PNA
showed variances in concentrations of solutes that are amino acid
metabolites and thus depending on protein intake, this was not the
case for b2M which, as a component of major histocompatibility
complex class I molecules, is of endogenous origin.
Our data might seemingly be in contradiction with the current
understanding that inadequate nutrition is an important predictor
of outcome in chronic hemodialysis patients [75–77], since low
values of PNA have been associated with higher morbidity and
mortality [78,79] whereas here they are linked to lower uremic
toxin concentrations. However, for several uremic retention
solutes such as AGEs and Hcy, a low rather than high
concentration has been associated with higher mortality in dialysis
patients [69–72]; these differences have been attributed to the fact
that the toxic effect of the molecules was overridden by the
deleterious impact of malnutrition and the lower intake of solutes
or their precursors when less food is entering the intestine [69,71].
For protein bound toxins, like indoxyl sulfate or p-cresylsulfate,
however, high, not low, concentration has repeatedly been
associated with mortality, even after adjustment for protein intake
parameters [39,40,42], suggesting that toxin concentration in this
case overrides the impact of nutrition on outcome. This does not
take away that low protein intake should be avoided in
hemodialysis patients due to its negative impact on outcome per
se [77,78]. Our data do not refute high protein intakes but are only
proof of concept that the intestinal protein load is an important
source of uremic toxins, and that therapeutic means to reduce this
(probiotics, prebiotics, sorbents), if they are not jeopardizing
nutritional status, may have added value to the removal obtained
by dialysis and should be explored and assessed in controlled trials.
Furthermore, PNA is not only a nutrition term but is also
influenced by the metabolic status of the patient. Examination of
the body weights during a period starting one month before until
one month after the study reveals however that 35% of the patients
are stable in weight, while only minor changes (1.8%) were seen in
the remaining group with a comparable number of patients with
increasing and decreasing body weight, respectively [69.0 (61.3–
78.8) kg]. Hence, changes in metabolic status in our patient
population did not influence correlations between PNA and
uremic toxin concentrations.
A small number of studies suggested that PNA linearly varies
with the dialysis dose Kt/Vurea [80,81], but the HEMO study
failed to demonstrate any significant change in protein intake
attributable to hemodialysis dose [82]. The present study as well
did not find any correlation between PNA and Kt/Vurea (data not
shown).
Strengths of this study are the assessment of a population from
one single unit where the same standards of treatment are applied
overall, and the inclusion of several parameters with the potential
impact on solute concentration. A shortcoming of this study is its
transversal nature with only one set of values per patient at one
single moment. However, an analysis using average Kt/Vurea of
the same population over a period of 3 months resulted in the
same conclusions (data not shown). In addition, single values of
PNA and RRF were used which nevertheless resulted in much
higher variances. An analysis using average PNA of the same
population over a period of 3 months resulted in even more
correlations with uremic toxin concentrations (i.e. also correlated
with free IS and free IAA concentrations). Another shortcoming
might have been the use of predialysis uremic toxin concentra-
tions. However, an analysis using the time averaged concentration
(TAC) of urea, the only solute of which the post dialysis value was
available to calculate TAC, gave similar results. Finally, the study
results for PNA could have been skewed by not considering the
urea concentration after post-dialysis rebound [83] and by only
looking at a midweek dialysis session possibly overestimating the
weekly value [84] and not including intraweek variability [85].
However, since overestimations by not considering urea rebound
are only in the range of 6% [83], since we considered midweek
sessions with similar dialysis durations (245618 min) which were
constant during the preceding three months, and since intraweek
variations (estimated being 9.3% [85]) are likely to be counter-
balanced among patients, our correlation analyses between PNA
and uremic toxin concentrations can be considered representative.
Conclusion
In conclusion, serum concentrations of most uremic toxins are
correlated with residual renal function and protein equivalent of
nitrogen appearance, and not with dialysis adequacy as assessed by
Kt/Vurea. Hence, we conclude from this observational study that
efforts to control intestinal load of uremic toxin precursors by
dietary or other interventions, and preserving RRF are important
approaches to decrease uremic solute concentration and by
extension their toxicity.
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